- Home
- PALI vs AARD Comparison
PALI vs AARD Comparison
Compare PALI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | AARD |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.2M | 281.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PALI | AARD |
|---|---|---|
| Price | $1.90 | $5.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $13.00 | ★ $19.63 |
| AVG Volume (30 Days) | ★ 2.8M | 325.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $260,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1500.39 | N/A |
| 52 Week Low | $0.55 | $4.74 |
| 52 Week High | $2.64 | $17.94 |
Technical Indicators
Market Signals| Indicator | PALI | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 57.27 | 24.24 |
| Support Level | $1.57 | $4.74 |
| Resistance Level | $1.93 | $15.88 |
| Average True Range (ATR) | 0.12 | 0.54 |
| MACD | 0.01 | -0.55 |
| Stochastic Oscillator | 86.79 | 12.99 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.